Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study
Eric S. Winer(Providence College), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Donald Richards(The US Oncology Network), Brendan M. Johnson(Research Triangle Park Foundation), Lee Hartner(Illinois CancerCare), Bogusława Karaszewska(State University of Applied Sciences in Konin), Conrad A. Messam(GlaxoSmithKline (United Kingdom)), Bhabita Mayer(GlaxoSmithKline (United Kingdom)), Frédéric Forget, Howard Safran(Brown University), Kirushna Kumar(Meenakshi Mission Hospital and Research Centre), Rodryg Ramlau(Poznan University of Medical Sciences)
Cited by 63
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
|Journal of Clinical Oncology|2009|1.5k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k